WO2011081430A3 - 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 - Google Patents

향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 Download PDF

Info

Publication number
WO2011081430A3
WO2011081430A3 PCT/KR2010/009476 KR2010009476W WO2011081430A3 WO 2011081430 A3 WO2011081430 A3 WO 2011081430A3 KR 2010009476 W KR2010009476 W KR 2010009476W WO 2011081430 A3 WO2011081430 A3 WO 2011081430A3
Authority
WO
WIPO (PCT)
Prior art keywords
water solubility
radiotherapy
preparation
composition containing
injection formulation
Prior art date
Application number
PCT/KR2010/009476
Other languages
English (en)
French (fr)
Other versions
WO2011081430A2 (ko
Inventor
강혜원
서민효
이사원
김봉오
최은경
정성윤
우하나
Original Assignee
주식회사 삼양사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 삼양사 filed Critical 주식회사 삼양사
Priority to US13/519,914 priority Critical patent/US20120276169A1/en
Priority to EP10841262.8A priority patent/EP2522338A4/en
Priority to CN201080060367.2A priority patent/CN102740834B/zh
Priority to JP2012547021A priority patent/JP2013516407A/ja
Publication of WO2011081430A2 publication Critical patent/WO2011081430A2/ko
Publication of WO2011081430A3 publication Critical patent/WO2011081430A3/ko
Priority to US14/231,355 priority patent/US9173841B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 향상된 수용해도를 갖는 라파마이신 함유 고분자 나노입자 주사제형 조성물, 보다 상세하게는 수용해도가 낮은 라파마이신을 고분자 나노입자로 가용화하여 수용해도를 향상시킨 라파마이신 함유 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물에 관한 것이다.
PCT/KR2010/009476 2009-12-30 2010-12-29 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 WO2011081430A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/519,914 US20120276169A1 (en) 2009-12-30 2010-12-29 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
EP10841262.8A EP2522338A4 (en) 2009-12-30 2010-12-29 POLYMERNANOPARTICLE INJECTION FORMULATION COMPOSITION WITH RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY COMPOSITION FOR COMBINED USE WITH RADIO THERAPY
CN201080060367.2A CN102740834B (zh) 2009-12-30 2010-12-29 具有提升的水溶解度的含雷帕霉素的高分子纳米粒子注射剂型组合物及其制备方法，以及用于与放射线疗法联用的抗癌组合物
JP2012547021A JP2013516407A (ja) 2009-12-30 2010-12-29 改善された水溶解度を有するラパマイシン含有高分子ナノ粒子注射剤組成物及びその製造方法、並びに放射線療法と併用するための抗癌組成物
US14/231,355 US9173841B2 (en) 2009-12-30 2014-03-31 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090134617 2009-12-30
KR10-2009-0134617 2009-12-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/519,914 A-371-Of-International US20120276169A1 (en) 2009-12-30 2010-12-29 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
US14/231,355 Division US9173841B2 (en) 2009-12-30 2014-03-31 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy

Publications (2)

Publication Number Publication Date
WO2011081430A2 WO2011081430A2 (ko) 2011-07-07
WO2011081430A3 true WO2011081430A3 (ko) 2011-11-10

Family

ID=44227032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/009476 WO2011081430A2 (ko) 2009-12-30 2010-12-29 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물

Country Status (6)

Country Link
US (2) US20120276169A1 (ko)
EP (1) EP2522338A4 (ko)
JP (2) JP2013516407A (ko)
KR (1) KR101267813B1 (ko)
CN (1) CN102740834B (ko)
WO (1) WO2011081430A2 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN107261154A (zh) 2011-04-29 2017-10-20 西莱克塔生物科技公司 致耐受性合成纳米载体
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
KR101508275B1 (ko) 2011-12-16 2015-04-08 주식회사 삼양바이오팜 고분자 나노입자 수용액 조성물 및 그 제조방법
US9278090B2 (en) * 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
CN110123759A (zh) * 2012-12-03 2019-08-16 曼丽国际有限公司 Umirolimus及其衍生物用于治疗癌症的用途
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CA2968049A1 (en) * 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP3189138A4 (en) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
EP3215192B1 (en) * 2014-11-05 2021-02-17 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
KR101726728B1 (ko) 2015-07-28 2017-04-14 주식회사 삼양바이오팜 고분자 담체 함유 약학 조성물의 유연물질 분석 방법
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3755303A1 (en) * 2018-02-23 2020-12-30 Biotronik AG Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
CN109646403B (zh) * 2019-01-11 2021-06-22 福州大学 一种无载体大环内酯类免疫抑制药物纳米粒的制备方法
CN110623925B (zh) * 2019-09-26 2021-06-25 严鹏科 一种雷帕霉素纳米缓释剂及其制备方法
CN115484931A (zh) * 2020-03-11 2022-12-16 西莱克塔生物科技公司 与合成纳米载体相关的方法和组合物
KR102584649B1 (ko) * 2021-07-13 2023-10-04 충북대학교 산학협력단 펜벤다졸 및 라파마이신이 봉입된 폴리에틸렌 글리콜-폴리카프로락톤 공중합체 마이셀 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650730A1 (en) * 1993-09-30 1995-05-03 American Home Products Corporation Rapamycin formulations for oral administration
US5530006A (en) * 1992-03-30 1996-06-25 American Home Products Corporation Rapamycin formulation for IV injection
US20040253195A1 (en) * 2001-10-18 2004-12-16 Min-Hyo Seo Polymeric michelle composition with improved stability
US20050201972A1 (en) * 2003-10-10 2005-09-15 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
WO2005107813A1 (en) * 2004-05-06 2005-11-17 Samyang Corporation Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
KR100360827B1 (ko) 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
KR20020063955A (ko) 2001-01-31 2002-08-07 엘지전자주식회사 음극선관용 전자총의 잔류유해가스 제거장치
CN100471886C (zh) * 2003-10-10 2009-03-25 株式会社三养社 两亲嵌段共聚物以及包含它的用于给药的聚合组合物
KR20050064075A (ko) * 2003-12-23 2005-06-29 주식회사 삼양사 이트라코나졸을 유효성분으로 하는 약학적 조성물
KR101118199B1 (ko) * 2004-12-20 2012-03-15 주식회사 삼양홀딩스 타크롤리무스를 가용화하기 위한 고분자 미셀 조성물
JP2008535927A (ja) * 2005-04-12 2008-09-04 ウィスコンシン アルムニ リサーチ ファンデイション ポリマー及びパッセンジャー薬のミセル組成物
PL2481402T3 (pl) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530006A (en) * 1992-03-30 1996-06-25 American Home Products Corporation Rapamycin formulation for IV injection
EP0650730A1 (en) * 1993-09-30 1995-05-03 American Home Products Corporation Rapamycin formulations for oral administration
US20040253195A1 (en) * 2001-10-18 2004-12-16 Min-Hyo Seo Polymeric michelle composition with improved stability
US20050201972A1 (en) * 2003-10-10 2005-09-15 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
WO2005107813A1 (en) * 2004-05-06 2005-11-17 Samyang Corporation Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. A. YANEZ ET AL.: "Pharmacometrics and delivery of novel nanoformulated PEG-b-poly (epsilon-caprolactone) micelles of rapamycin", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 61, no. 1, January 2008 (2008-01-01), pages 133 - 144 *

Also Published As

Publication number Publication date
CN102740834A (zh) 2012-10-17
US20140212462A1 (en) 2014-07-31
JP2013516407A (ja) 2013-05-13
CN102740834B (zh) 2017-04-05
EP2522338A2 (en) 2012-11-14
JP2015078247A (ja) 2015-04-23
KR20110079518A (ko) 2011-07-07
US9173841B2 (en) 2015-11-03
KR101267813B1 (ko) 2013-06-04
WO2011081430A2 (ko) 2011-07-07
EP2522338A4 (en) 2013-09-18
US20120276169A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2011081430A3 (ko) 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2011080148A3 (en) An aqueous intravenous nanosuspension with reduced adverse effects
WO2011017690A3 (en) Intracellular delivery of contrast agents with functionalized nanoparticles
WO2011009539A8 (de) ε-POLYLYSIN-KONJUGATE UND DEREN VERWENDUNG
EP2166060B8 (en) Stabilized aqueous polymer compositions
WO2011091411A3 (en) Polyesters, methods of making polyesters and uses therefor
WO2010096733A3 (en) Luminescent porous silicon nanoparticles, methods of making and using same
WO2012061607A3 (en) Compositions comprising functionalized carbon-based nanostructures and related methods
WO2011073341A3 (de) Polymerdispersionen
WO2012019427A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
PT2594140T (pt) Nanopartículas para encapsulamento de compostos, sua produção e utilizações
WO2012078902A3 (en) Proteostasis regulators
WO2012031164A3 (en) Drug delivery by carbon nanotube arrays
WO2011050177A8 (en) Paa nanoparticles for enhancement of tumor imaging
EP2488023A4 (en) ANTIMICROBIAL COMPOSITION
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2011100671A3 (en) Methods and compositions to improve mechanical resistance of teeth
WO2013103301A3 (en) Method for preparing cell targeting conjugates, and the complexes obtained
WO2012120098A3 (fr) Pigments traités hydrophiles dispersibles dans une composition cosmétique
WO2010117199A3 (ko) 코엔자임 q10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EP4349369A3 (en) Increasing drug bioavailability in naltrexone therapy
WO2012151242A3 (en) Lignin-based nanostructures

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080060367.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10841262

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010841262

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012547021

Country of ref document: JP

Ref document number: 13519914

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE